HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp-120 CCR5 engagement that attenuates macrophage.

Slides:

Advertisements

Similar presentations

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Advertisements

Faculty for This Activity

Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.

Monogram Biosciences Pharma Collaborations

Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.

Antiviral Immunity and Transmission June 19, 2011 Abst. #: TUAA0105 Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly.

+ Antiretroviral Agents: HIV & AIDS Shaw Vonder Hoya.

Chemokine Receptor 5 Inhibition Prevents SIV-associated Cardiac Dysfunction Katie Kelly Brennan, DVM Johns Hopkins University School of Medicine Department.

Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.

HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).

Lecture: HIV I.Motivation What can we learn when we apply evolutionary principles to our understanding of the of the HIV epidemic?? Can we use HIV to introduce.

An Introduction to the HIV Problem Space Oakwood University: Faculty Quantitative Institute Aug. 10–12, 2009.

HIV Structure, Lifecycle, and Replication

HIV = Human Immunodeficiency Virus

Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.

Viruses that Use Reverse Transcriptase during Replication The retroviruses have an RNA genome that is converted to DNA by RT after infection. The hepadnaviruses.

The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.

Future directions in HIV basic science research The hunt for a cure.

Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.

Plate 87 Acquired Immune Deficiency Syndrome (AIDS)

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 93 Antiviral Agents II: Drugs for HIV Infection and Related.

THE IMMUNOPATHOGENESIS OF HIV INFECTION. THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) 10359bp DNA gp120 gp41 CD4 binding Membrane fusion.

CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

Future directions in HIV basic science research The hunt for a cure.

The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.

Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --

Anti-HIV Drugs Melissa Morgan Medicinal Chemistry November 23, 2004.

1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.

Immunodeficiency syndromes. Classification Primary:rare,B,T & combined B &T deficits Secondary: in severe infection, immunosupression(CT,RT),malnutrition,DM,renal.

Project 2: Cellular Mechanisms and Interaction of Neurokinin-1 Receptor (NK- 1R) Antagonists and HIV Co- Receptors CCR5 and CXCR4 Principal Investigator.

Project 1: Anti-HIV Mechanisms of NK-1R Antagonists PI: Wenzhe Ho Co-PI: Steven D. Douglas.

Evolution is the unifying concept of biology. Two Central Themes of Biology Adaptation - How and in what ways do organisms function and become better.

Introduction: Red blood cells can theoretically be used as a platform for therapeutic proteins because they are both long lived and naturally occur in.

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - Heribert Knechten, MD PZB Aachen, Germany T = 5.

Phenotypic properties influencing HIV-1 transmission fitness IAS Conference on HIV Pathogenesis, Treatment & Prevention Vancouver July 21 st 2015 Katja.

Receptor/enzymes. Drug Design Most drugs work on proteins Somehow interfere with a biochemical process –Can shut down –Can activate.

Future directions in HIV basic science research The hunt for a cure.

Why study evolution?  Best conceptual framework for understanding origins of biodiversity  Adaptations that allow organisms to exploit their environment.

Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc Add-On Therapy for 8 Days *Rachel A. McGovern, Art F.Y.

Remodeling of gp-41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with target cells Promising anti-1 peptide developed Nina Pollak.

I guess you think you know this story. You don’t. The real one’s much more gory. The phoney one, the one you know Was cooked up years and years ago.” Roald.

Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.

Z Su, JD Reeves, A Krambrink, E Coakley, M Hughes, C Flexner, T Wilkin, P Skolnik, W Greaves, D Kuritzkes, R Gulick, ACTG 5211 Team Response to Vicriviroc.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

HIV Life Cycle Step 1: Fusion Step 2: Transcription reverse transcriptase Step 3: Integration Step 4: Cleavage Step 5: Packaging and Budding HIV.

Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow.

Retrovirus. Retroviridae –Retrovirus HTLV (human T-cell lymphotropic virus) –Lentivirus HIV.

THE IMMUNE RESPONSES TO VIRUSES

Lecture - Dec 1, 2015 Receptor-mediated Entry of HIV-1 into Cells: A Target for Prevention and Treatment Purposes.

ROLE OF CCR5 LEVELS IN HIV-1 EVOLUTION AND PATHOGENESIS ANJALI JOSHI Assistant Professor Center of Emphasis in Infectious Diseases Department of Biomedical.

THE IMMUNOPATHOGENESIS OF HIV INFECTION Lymphotropic virus.

Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.

HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.

Virological and immunological efficacy of regimen including MVC

Katsin MA, Vitebsk State Medical University (Belarus)

Viral Genetics.

UK-CAB: Entry inhibitors and Immunology 3 June 2005

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis Dao X. Nguyen, BSc, Alice Cotton, RN, BSc, Laura Attipoe, MBBS, Coziana.

Amino Acid Sequences in V3 Loop Conformation

Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.

Monique Nijhuis University Medical Center Utrecht, the Netherlands

Analysis of co‐receptor usage of circulating viral and proviral HIV genome quasispecies by ultra‐deep pyrosequencing in patients who are candidates for.

Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.

Michael S. Glickman, Charles L. Sawyers Cell

PubMed Research Article

Presentation transcript:

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp-120 CCR5 engagement that attenuates macrophage tropism Michael Roche PhD Student Burnet Institute

HIV Resistance to Maraviroc HIV uses CD4 as the primary receptor and either CCR5 or CXCR4 as a coreceptor for entry Maraviroc (MVC) is the first approved drug in a new class of entry inhibitors – CCR5 antagonists Bind and lock CCR5 in a conformation not recognized by HIV Env – allosteric inhibition HIV can become resistant to MVC by emergence pre-existing CXCR4 using variants or by using the MVC modified form of CCR5 Characterized by plateaus in inhibition (MPI) – non-competitive resistance Is there an infectivity cost associated with using the MVC modified form of CCR5, such as changes in cell tropism? Competitive ResistanceNon-competitive Resistance

MVC attenuates Macrophage tropism of MVC resistant Env MVC resistant Env from isolate generated in vitro Characteristic resistant phenotype High plateau – low level of resistance Associated with a less efficient gp120-CCR5 interaction Does this alter the cell tropism of the resistant virus? MVC attenuates macrophage but not PBMC infection Infectivity cost associated with resistance for this in vitro generated virus

Level of MVC resistance in vivo is associated with the level of attenuation of Macrophage tropism by MVC Envs cloned from 2 patients who failed MVC therapy with CCR5-using virus Patient 17 displays high plateau, thus ‘very weak’ resistance Patient 24 displays lowered plateau, thus ‘strong’ resistance Level of resistance associates with attenuation of macrophage infection by MVC Patient 17 ‘Very Weak’ Resistance Patient 24 ‘Strong’ Resistance Conclusion: Maintaining MVC despite the development of resistance (in some cases) may spare the macrophage reservoir from infection and thus may have some clinical benefit

Acknowledgments Gorry Lab Paul Gorry Melissa Churchill Jasminka Sterjovski Anne Ellett Miranda Moore Hamid Salimiseyedabad Martin Jakobsen Kieran Cashin Lachlan Gray Daniel Cowley Paul Ramsland Sharon Lewin Pfizer Ltd Mike Westby Becky Jubb UCLA Benhur Lee Fillipo Posta